LBT Innovations (ASX:LBT) - Managing Director & CEO, Brent Barnes
Managing Director & CEO, Brent Barnes
Source: LBT Innovations
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) has received firm commitments to raise $8 million via a share placement, adding several new institutional investors to the register
  • The Australian medical technology company has also launched a share purchase plan (SPP) with hopes to raise another $1 million
  • Funds from the placement and SPP will be directed towards accelerating commercialisation activities in Europe, including under a new marketing partnership with Beckman Coulter
  • Along with existing cash reserves, the capital raising will provide the company with a funding runway into 2022
  • LBT shares are trading flat for 19 cents each at open

LBT Innovations (LBT) has received firm commitments from sophisticated and professional investors to raise $8 million via a share placement.

The placement

The Australian medical technology company received these commitments from both existing shareholders and several new institutional investors.

Under the placement, LBT will issue 50 million new fully paid ordinary shares at an issue price of 16 cents each which represents a 21.9 per cent discount to the five-day volume-weighted average price.

The issue will not require shareholder approval, as the shares will be issued under the company’s existing placement capacity around July 15, 2020.

The Share purchase plan

LBT has also launched a share purchase plan (SPP) targeting an additional $1 million but has reserved the right to accept oversubscriptions.

Eligible shareholders will be able to subscribe for up to $30,000 worth of new shares for 16 cents per share.

Use of the funds

Funds from the placement and SPP will be directed towards accelerating commercialisation activities in Europe, including under a new marketing partnership with Beckman Coulter that was announced on Tuesday.

Additionally, the funds will support ongoing commercialisation activities in the United States, the development of the Automated Plate Assessment System (APAS) analysis module and provide working capital.

Along with the LBT’s $7.1 million in cash as at June 30, 2020, the capital raising will provide the company with a funding runway into 2022.

LBT shares are trading flat for 19 cents each at market open.

LBT by the numbers
More From The Market Online
The Market Online Video

Recce progresses testing of gel to treat bacterial skin infections

Recce Pharmaceuticals Ltd has reached an important milestone in testing of its R327G gel to treat…
Burn wound care

Orthocell wins first international approval for nerve repair product

West Australia-based regenerative medicine play Orthocell (ASX: OCC) has received regulatory approval from the Health Sciences…
Map showing Valeriepieris Circle - a relatively small area of Earth’s surface that contains half the human population.

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical…
The Market Online Video

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical…